Verrica Pharmaceuticals Inc. (VRCA) Operating Margin
- Operating margin · 12 months: Value -93.59%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -93.59% | Operating income / revenue. Period ending 2026-06-30. $-28.38M ÷ $30.32M × 100 ≈ -93.59% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -28.38M USD | Operating Income (Loss) |
| Revenue | 30.32M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 14.62M USD | Research and Development Expense |
| Selling, general and administration | 37.86M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-28.38M | $30.32M | (m) | $14.62M | $37.86M | -93.59% |
| 2026-03-31 | $-13.77M | $37.16M | (m) | $10.43M | $36.36M | -37.05% |
| 2025-12-31 | $-12.19M | $35.58M | (m) | $8.86M | $35.22M | -34.25% |
| 2025-09-30 | $-16.40M | $30.83M | (m) | $7.50M | $36.98M | -53.21% |
| 2025-06-30 | $-38.73M | $14.70M | (m) | $7.70M | $43.66M | -263.42% |
| 2025-03-31 | $-55.45M | $7.18M | (m) | $9.18M | $51.33M | -772.39% |
| 2024-12-31 | $-65.92M | $7.57M | (m) | $11.84M | $58.82M | -871.25% |
| 2024-09-30 | $-77.64M | $9.21M | (m) | $15.99M | $65.94M | -843.05% |
| 2024-06-30 | $-80.86M | $13.91M | (m) | $20.10M | $69.91M | -581.38% |
| 2024-03-31 | $-77.27M | $8.91M | (m) | $22.50M | $59.33M | -866.92% |
| 2023-12-31 | $-65.76M | $5.12M | (m) | $20.30M | $47.30M | -1283.35% |
| 2023-09-30 | $-48.83M | $3.20M | (m) | $18.00M | (m) | -1524.16% |
| 2023-06-30 | $-23.47M | $8.61M | (m) | $14.27M | (m) | -272.72% |
| 2023-03-31 | $-20.98M | $8.64M | (m) | $12.49M | (m) | -242.82% |
| 2022-12-31 | $-21.30M | $9.03M | (m) | $12.20M | (m) | -235.78% |
| 2022-09-30 | $-23.55M | $8.96M | (m) | $13.19M | (m) | -262.77% |
| 2022-06-30 | $-36.77M | $645.00K | (m) | $14.01M | (m) | -5700.62% |
| 2022-03-31 | $-38.38M | $431.00K | (m) | $13.29M | (m) | -8904.41% |
| 2021-12-31 | $-30.91M | $12.00M | (m) | $15.93M | (m) | -257.57% |
| 2021-09-30 | $-34.47M | (m) | (m) | $14.84M | (m) | (m) |
| 2021-06-30 | $-32.34M | (m) | (m) | $16.07M | (m) | (m) |
| 2021-03-31 | $-30.24M | (m) | (m) | $16.14M | (m) | (m) |
| 2020-12-31 | $-40.18M | (m) | (m) | $15.67M | (m) | (m) |
| 2020-09-30 | $-36.14M | (m) | (m) | $17.37M | (m) | (m) |
| 2020-06-30 | $-33.04M | (m) | (m) | $15.43M | (m) | (m) |
| 2020-03-31 | $-31.93M | (m) | (m) | $15.84M | (m) | (m) |
| 2019-12-31 | $-30.08M | (m) | (m) | $15.44M | (m) | (m) |
| 2019-09-30 | $-30.28M | (m) | (m) | $16.38M | (m) | (m) |
| 2019-06-30 | $-30.07M | (m) | (m) | $16.80M | (m) | (m) |
| 2019-03-31 | $-28.02M | (m) | (m) | $16.39M | (m) | (m) |
| 2018-12-31 | $-21.88M | (m) | (m) | $12.83M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-5.78M | (m) | (m) | $4.14M | (m) | (m) |
| 2017-12-31 | $-4.46M | (m) | (m) | $3.73M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |